Compare · DXCM vs TTOO
DXCM vs TTOO
Side-by-side comparison of DexCom Inc. (DXCM) and T2 Biosystems Inc. (TTOO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DXCM and TTOO operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $28.11B, about 449.8x TTOO ($62.5M).
- Over the past year, DXCM is down 14.9% and TTOO is up 0.0% - TTOO leads by 14.9 points.
- DXCM has hit the wire 26 times in the past 4 weeks while TTOO has been quiet.
- DXCM has more recent analyst coverage (25 ratings vs 1 for TTOO).
- Company
- DexCom Inc.
- T2 Biosystems Inc.
- Price
- $72.84+0.38%
- $0.13-34.35%
- Market cap
- $28.11B
- $62.5M
- 1M return
- +20.73%
- +0.00%
- 1Y return
- -14.94%
- +0.00%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2005
- 2014
- News (4w)
- 26
- 0
- Recent ratings
- 25
- 1
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
T2 Biosystems Inc.
T2 Biosystems, Inc., an in vitro diagnostics company, develops diagnostic products and product candidates in the United States and internationally. It provides T2 Magnetic Resonance technology that enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine. The company also offers T2Dx Instrument, a bench-top instrument for detecting pathogens associated with sepsis and Lyme disease, and other applications, as well as T2Candida Panel that identifies the species of Candida, a fungal pathogen known to cause sepsis directly from whole blood. In addition, it provides T2Bacteria Panel, a multiplex diagnostic panel that detects various bacterial pathogens associated with sepsis; T2SARS-CoV-2 Panel, a COVID-19 molecular diagnostic test; and T2Resistance Panel for the early and sensitive detection of carbapenemase-resistance markers. Further, it develops T2Cauris Panel, a multi-drug resistant pathogen; and T2Lyme Panel for the detection of various strains of Lyme disease-causing bacteria. The company has collaboration agreements with Canon U.S. Life Sciences, Inc. to develop a diagnostic test panel to detect Lyme disease. T2 Biosystems, Inc. was incorporated in 2006 and is headquartered in Lexington, Massachusetts.
Latest DXCM
- Dexcom CONNECT Study: The Most Significant Clinical Study Demonstrating CGM Benefits for People with Type 2 Diabetes Not Using Insulin
- EVP, Chief Commercial Officer Coleman Jon sold $722,628 worth of shares (9,823 units at $73.56) as part of a pre-agreed trading plan, decreasing direct ownership by 9% to 95,450 units (SEC Form 4)
- Dexcom Reaffirms CGM Benefits for All People With Diabetes and Continues Momentum Toward Earlier Stage Intervention and Preventative Care at ADA 2026
- Dexcom Releases Customer Advisory Council Report, Outlining Ongoing Commitments to Enhancing Product Performance and User Experience
- Director Altman Steven R was granted 5,565 shares (SEC Form 4)
- Director Augustinos Nicholas was granted 5,575 shares (SEC Form 4)
- Director Malady Kyle was granted 5,575 shares, increasing direct ownership by 25% to 28,242 units (SEC Form 4)
- Director Heller Bridgette P was granted 5,575 shares, increasing direct ownership by 22% to 30,582 units (SEC Form 4)
- Director Osterloh Albert Frederick Iv was granted 1,630 shares, increasing direct ownership by 23% to 8,691 units (SEC Form 4)
- Director Foletta Mark G was granted 6,331 shares (SEC Form 4)
Latest TTOO
- Amendment: SEC Form 25-NSE/A filed by T2 Biosystems Inc.
- SEC Form 25-NSE filed by T2 Biosystems Inc.
- SEC Form 8-K filed by T2 Biosystems Inc.
- SEC Form NT 10-K filed by T2 Biosystems Inc.
- SEC Form 8-K filed by T2 Biosystems Inc.
- T2 Biosystems Inc. filed SEC Form 8-K: Costs Associated with Exit or Disposal Activities
- Amendment: SEC Form SCHEDULE 13G/A filed by T2 Biosystems Inc.
- SEC Form 8-K filed by T2 Biosystems Inc.
- SEC Form DEF 14A filed by T2 Biosystems Inc.
- SEC Form 8-K filed by T2 Biosystems Inc.